Skip to main content

Table 3 Associations between reproductive health characteristics and serological reactivity for HPV16

From: Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study

Characteristic and categories HPV16 seroreactivity 425/1624 (%)* OR (95%CI)**
Unadjusted Adjusted (HPV16 and age)
Oral Contraceptives:    
Never 60/264 (18.5) 1.0 1.0
<6 years 235/885 (21.0) 1.17 (0.85-1.60) 1.21 (0.88-1.67)
6+ years 130/475 (21.5) 1.20 (0.86-1.69) 1.07 (0.76-1.51)
Inter-uterine Device (IUD):    
Never 281/1010 (21.8) 1.0 1.0
Ever 144/614 (19.0) 0.84 (0.67-1.05) 0.88 (0.70-1.10)
Condom Use:    
Never 177/600 (22.8) 1.0 1.0
Rarely 144/574 (20.1) 0.85 (0.66-1.09) 0.88 (0.66-1.08)
Sometimes/always 98/423 (18.8) 0.78 (0.59-1.02) 0.84 (0.63-1.12)
Menstrual Cycle***:    
Follicular phase 185/745 (19.9) 1.0 1.0
Luteal phase 136/526 (20.5) 1.04 (0.81-1.33) 1.04 (0.81-1.34)
Parity:    
0-1 55/277 (16.6) 1.0 1.0
2-4 237/943 (20.1) 1.27 (0.92-1.74) 1.16 (0.83-1.61)
5+ 133/389 (25.5) 1.72 (1.21-2.44) 1.38 (0.94-2.01)
Abortion:    
No abortion 216/804 (21.2) 1.0 1.0
One abortion 96/338 (22.1) 1.05 (0.80-1.38) 0.99 (0.75-1.31)
2+ abortions 77/262 (22.7) 1.09 (0.81-1.47) 0.98 (0.72-1.33)
Vaginal Douching:    
Never/occasional 379/1457 (20.6) 1.0 1.0
Frequent 26/95 (21.5) 1.06 (0.67-1.66) 1.06 (0.67-1.67)
  1. *Frequencies above and below the threshold for the top 20% quintile and percentage with high seroreactivity; **Odds ratios and respective 95% confidence intervals. First category in each variable is the referent; ***At the time of specimen collection: follicular (before 14 days) and luteal phase (after 14 days). Post-menopausal women and women with irregular cycles were not included in the analysis.